InSite rationalizes

InSite Vision Inc. said it is tightening its strategic focus to concentrate on its clinical candidates for glaucoma and pterygium, a non-cancerous growth on the eye, which offer the greatest near term potential. The products include BetaSite, a formulation of the beta blocker levobunolol in INSV's DuraSite bioadhesive polymer, and PilaSite, a similar formulation of pilocarpine. Both are being developed for glaucoma.

INSV just announced positive results of its Phase III trials of BetaSite (see page B6) and has completed patient treatment in a second Phase III study of PilaSite, with results expected mid-year. INSV will seek corporate partners to market these products outside the U.S., and also will seek partners for products it doesn't plan to develop on its own...